Last reviewed · How we verify

Basal Insulin and Bolus Insulin

Rabin Medical Center · Phase 3 active Small molecule

Basal Insulin and Bolus Insulin is a Insulin therapy (basal-bolus regimen) Small molecule drug developed by Rabin Medical Center. It is currently in Phase 3 development for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring intensive insulin therapy. Also known as: glargine, glulisine, Basal insulin glargine, Pre-meal insulin lispro.

Basal-bolus insulin therapy mimics physiological insulin secretion by combining long-acting basal insulin for fasting glucose control with rapid-acting bolus insulin for postprandial glucose management.

Basal-bolus insulin therapy mimics physiological insulin secretion by combining long-acting basal insulin for fasting glucose control with rapid-acting bolus insulin for postprandial glucose management. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring intensive insulin therapy.

At a glance

Generic nameBasal Insulin and Bolus Insulin
Also known asglargine, glulisine, Basal insulin glargine, Pre-meal insulin lispro
SponsorRabin Medical Center
Drug classInsulin therapy (basal-bolus regimen)
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Basal insulin provides steady background insulin levels to suppress hepatic glucose production and maintain fasting blood glucose, while bolus insulin is administered at mealtimes to counteract postprandial glucose excursions. Together, this regimen approximates the body's natural biphasic insulin secretion pattern, improving overall glycemic control in insulin-dependent diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Basal Insulin and Bolus Insulin

What is Basal Insulin and Bolus Insulin?

Basal Insulin and Bolus Insulin is a Insulin therapy (basal-bolus regimen) drug developed by Rabin Medical Center, indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring intensive insulin therapy.

How does Basal Insulin and Bolus Insulin work?

Basal-bolus insulin therapy mimics physiological insulin secretion by combining long-acting basal insulin for fasting glucose control with rapid-acting bolus insulin for postprandial glucose management.

What is Basal Insulin and Bolus Insulin used for?

Basal Insulin and Bolus Insulin is indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring intensive insulin therapy.

Who makes Basal Insulin and Bolus Insulin?

Basal Insulin and Bolus Insulin is developed by Rabin Medical Center (see full Rabin Medical Center pipeline at /company/rabin-medical-center).

Is Basal Insulin and Bolus Insulin also known as anything else?

Basal Insulin and Bolus Insulin is also known as glargine, glulisine, Basal insulin glargine, Pre-meal insulin lispro.

What drug class is Basal Insulin and Bolus Insulin in?

Basal Insulin and Bolus Insulin belongs to the Insulin therapy (basal-bolus regimen) class. See all Insulin therapy (basal-bolus regimen) drugs at /class/insulin-therapy-basal-bolus-regimen.

What development phase is Basal Insulin and Bolus Insulin in?

Basal Insulin and Bolus Insulin is in Phase 3.

What are the side effects of Basal Insulin and Bolus Insulin?

Common side effects of Basal Insulin and Bolus Insulin include Hypoglycemia, Weight gain, Injection site reactions, Lipodystrophy.

What does Basal Insulin and Bolus Insulin target?

Basal Insulin and Bolus Insulin targets Insulin receptor and is a Insulin therapy (basal-bolus regimen).

Related